Fintech▲ 80

Knight Therapeutics reports record results

Globenewswire·March 19, 2026 at 11:30 AM

Knight Therapeutics has announced record-high revenues, Adjusted EBITDA, and Adjusted EBITDA per share for its fourth quarter and full year 2025. The company also achieved record cash flow from operations. These strong financial results underscore Knight Therapeutics' successful performance and growth trajectory within the pharmaceutical sector, highlighting effective strategic execution and market penetration.

Knight Therapeutics reports record results

OpenAI, Google refine AI commerce strategies

Nevada bars Kalshi from offering event contracts

Federal Reserve orders SVB collapse review

Centralizing Treasury Operations Offers Key Benefits